US Edition
News from neurologylive.com
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top neurologylive.com News
FDA · United StatesThe Food and Drug Administration said Friday it will add a new warning and other limitations to a gene therapy for Duchenne’s muscular dystrophy that’s been linked to two patient deaths.See the Story
FDA Adds Strongest Warning to Sarepta Gene Therapy for Duchenne’s Linked to 2 Patient Deaths
80% Center coverage: 71 sources
Pharma · United StatesNew York, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today called the U.S. Food and Drug Administration’s approval of Itvisma (onasemnogene abeparvovec-brve), developed by Novartis, a major step forward for families living with spinal muscular atrophy…See the Story
Muscular Dystrophy Association Calls FDA Approval of Novartis’ Itvisma (Onasemnogene ...
60% Center coverage: 25 sources
